Status:
UNKNOWN
The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer
Lead Sponsor:
Seoul National University Hospital
Conditions:
Pancreatic Adenocarcinoma
Chemotherapy Effect
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
Pancreatic cancer is a very poor prognosis and has a high mortality rate. The clinical results have improved somewhat with the combination therapy of chemotherapy as the first-line treatment. However,...
Detailed Description
Pancreatic cancer is a very poor prognosis and has a high mortality rate. It is not clear that the improvement of clinical outcome due to anticancer drugs is not clear compared to other carcinomas. In...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Patient whose age is 20 years or older
- ECOG Performance Status 0-2
- Pathologically confirmed pancreatic adenocarcinoma
- Patients with locally advanced or distant metastasis status
- Patients who had undergone primary chemotherapy with previous FOLFIRINOX and whose disease progress was confirmed
- Patients whose consent was obtained (non-insurance agreement)
- Exclusion Criteria
- Those who can not obtain consent
- Those who refuse chemotherapy
- ECOG Performance Status 3 or higher
- Multiple organ failure is accompanied
- Severe comorbidities other than cancer that do not expect a sufficient survival period over 1 month
- Allergy to the test drug
Exclusion
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03401827
Start Date
March 1 2018
End Date
January 1 2019
Last Update
February 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 110-744